Kornimate/medical-research-clean huggingface dataset:
a dual-targeting tracer tate-rgd for the diagnosis of sstr- and rgd- positive tumors

Conditions: Iodine-resistant Thyroid Cancer; Meningioma; NETs

Summary: the us fda approved a targeted somatostatin receptor 2 imaging agent, 68ga-dotatate, in 2016. it has higher uptake in small cell lung cancer, pulmonary carcinoid, and medullary thyroid cancer. integrin αvβ3 is highly expressed in some tumor cells and new blood vessels, making it an ideal target for targeted diagnosis and treatment of tumors and tumor vessels.68ga-labeled dota-tate-rgd is a new type of tumor-specific imaging agent developed by researchers based on the above foundation, which is used for targeted diagnosis and internal radiation therapy for patients with sstr2 and αvβ3 positive tumors.

this research has conducted extensive studies on the treatment of neuroendocrine tumors with 177lu-eb-tate and the treatment of fap-expressing tumors with 177lu-eb-fapi. the same protocol had demonstrated 68ga-tate-rgd showed an increasing tbr, suggesting the tracer kinetic advantage of tate-rgd. compared to the single-target tracer dotatate, the dual-target tate-rgd probe has a clear advantage in detecting nets liver metastases, and it can be explored for potential therapeutic uses in future studies and used for related companion diagnostics in targeted radiolabeling therapy (rlt), which has been published in the 1st-impact factor journal european journal of nuclear medicine and medical imaging (if: 9.6), performing a small-dose diagnostic pet imaging with the same tracer.

Eligibility criteria:
inclusion criteria: * histologically confirmed various cancer patients; * 68ga-tate-rgd and 18f-fdg pet/ct within a week; * signed written consent. exclusion criteria: * known allergy against tate-rgd; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
fluorouracil-uracil and leucovorin in treating elderly patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of fluorouracil-uracil and leucovorin in treating elderly patients who have metastatic colorectal cancer.

objectives: i. determine the response rate of elderly patients with metastatic colorectal cancer treated with fluorouracil-uracil and leucovorin calcium (orzel). ii. evaluate the toxicity profile of this regimen in this patient population. iii. compare response rates obtained in this study with those observed in recent phase iii studies in younger patients. outline: patients receive oral fluorouracil-uracil and oral leucovorin calcium (orzel) every 8 hours for 28 days. courses repeat every 35 days in the absence of unacceptable toxicity or disease progression. patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. projected accrual: a total of 20-55 patients will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: histologically confirmed metastatic colorectal adenocarcinoma measurable disease patient characteristics: age: 75 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 mg/dl ast or alt no greater than 2.5 times upper limit of normal (uln) renal: creatinine no greater than 1.5 times uln other: no serious infection no other serious underlying medical condition that would preclude protocol therapy no known hypersensitivity to fluorouracil-uracil or leucovorin calcium prior concurrent therapy: biologic therapy: at least 6 months since prior adjuvant immunotherapy for colorectal cancer no concurrent immunotherapy chemotherapy: at least 6 months since prior adjuvant chemotherapy for colorectal cancer no other concurrent chemotherapy endocrine therapy: no concurrent hormonal therapy radiotherapy: see disease characteristics at least 6 months since prior adjuvant radiotherapy for colorectal cancer prior radiotherapy for locally symptomatic disease allowed surgery: prior surgery allowed other: no prior therapy for metastatic disease no other concurrent investigational drugs no concurrent halogenated antiviral agents (e.g., lodenosine, fialuridine, fmau, emtricitabine, and sorivudine)

Keywords: stage iii colon cancer stage iv colon cancer stage iii rectal cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum
swiss postpartum hypertension cohort

Conditions: Postpartum Hypertension (PPHT)

Summary: this open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors/risk factors associated with long term cardiovascular and renal risk. current disease management strategies will be evaluated.


Eligibility criteria:
inclusion criteria: * all women with hypertensive disorders of pregnancy * postpartum hypertension (blood pressure measurements of systolic ≥140 and/or diastolic ≥ 90mmhg or antihypertensive therapy within the first 14 days after delivery) * women with preexisting hypertension or * women on antihypertensive medication exclusion criteria: * delivery \> 14 days * lack of consent to participate in the study, language barriers or lack of general understanding

Keywords: pregnancy induced hypertension (pih) home blood pressure monitoring (hbpm) office blood pressure monitoring (obpm) automated office blood pressure measurement (aobpm) gestational hypertension hekahealth self-measured blood pressure (smbp) app
early levothyroxine post radioactive iodine

Conditions: Graves' Disease

Summary: the study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for graves'disease will prevent overt hypothyroidism (low thyroid hormone levels).


Eligibility criteria:
inclusion criteria: -all adult patients (ages 18-70 years) with graves' disease (gd) who will receive radioactive iodine (rai) ablation of the thyroid gland for treatment of gd exclusion criteria: * clinically manifest graves' ophthalmopathy (go) * recent (\<1 yr.) history of arrhythmias or any history of ventricular arrhythmias * preexistent cardiomyopathy * malnutrition * psychiatric history that could get worse if patient remains persistently hyperthyroid * unlikely to return for the planned follow-up visits * unlikely to comply with the blood drawing schedule * unlikely to complete the hypothyroid-health related quality of life (hdql) and thyroid specific (tsq) questionnaires

Keywords: graves' disease radioactive iodine hypothyroidism
pulmonary fibrosis after severe covid-19 pneumonia

Conditions: Pulmonary Fibrosis; COVID-19

Summary: patients discharged after hospitalization for covid-19 pneumonia were retrospectively selected by radiologically established criteria that at admission presented at chest computed tomography (ct) (i) normal lung parenchyma \ 10%. all at discharge and after 9 months, all subjects underwent cardiological evaluation, echocardiogram, pulmonary function tests (pft) both atby 3 and by 12 months after discharge. chest ct was performed by 12 months after discharge and chest ct. specifically, the magnitude of pulmonary involvement between baseline and follow-up was considered the primary endpoint of this study. secondary endpoints of the study were results of respiratory function testing, echocardiographic parametersparameters, and persistence of symptoms.


Eligibility criteria:
inclusion criteria: * age ≥ 18 * hospitalization for severe covid-19 pneumonia * computed tomography during index hospitalization that showed: (i) normale lung parenchyma \ 10% * cardiological and pneumological visit, echocardiography and pulmonary function test at 3 and 12 months from hospital discharge * computed tomography by 12 months from hospital discharge exclusion criteria: * age \< 18 * absence of previously cited test.

Keywords: covid-19 pulmonary fibrosis ards computed tomography pulmonary function test
efficacy and safety study to evaluate gadavist (gadobutrol) as contrast agent in magnetic resonance imaging (mri) of brain or spine diseases in chinese patients

Conditions: Central Nervous System Diseases

Summary: the purpose of this study is to determine if the contrast agent is effective and safe in the magnetic resonance imaging (mri) of brain or spine diseases in patients of chinese origin.

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer healthcare ag, germany. bayer healthcare ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * chinese origin, with known or suspected brain or spine diseases exclusion criteria: * pregnancy * lactation * conditions interfering with mri * allergy to any contrast agent or any drugs * participation in other trial * require emergency treatment * severely impaired liver and kidney functions

Keywords: gadovist gadavist contrast agent brain spine disease magnetic resonance imaging
evaluation of physical performance and functional asymmetries in female football

Conditions: Resistance Training; Inter-limb Asymmetries; Athletic Performance

Summary: worldwide, soccer has grown increasingly popular among female players. according to the women´s football survey of the fédération internationale de football association (fifa), there were more than 30 million registered women soccer players in 2014. elite female soccer players cover approximately a total distance of 10 km with 1.7 km completed at high-speed (\>18 km/h-1), between 1350 and 1650 changes of activity like passing, dribbling, tackling and trapping and 5.1 and 31.2 repeated sprinting and high intensity bouts, respectively. thus, it seems that those strategies addressed to improve such high-intensity activities should be considered a priority for female soccer players. different training methods to improve soccer specific variables have been developed such as, high-intensity interval training, resisted sprint training, strength training or plyometric training. whilst individual training interventions have been shown to produce enhancements in measures of athletic performance for soccer players, there is a paucity of studies looking at the effectiveness of strength and power training specifically on performance measures in female soccer populations. unilateral strength asymmetry can be a risk factor of musculoskeletal injuries. in recent years, inter-limb asymmetries have been included in battery tests performed by different soccer clubs due to their relation with lower-limb injuries. few studies have analysed the change of an intervention on inter-limb asymmetry in female soccer players, hence, more studies for this population are warranted. the main aim of this research project is therefore, to evaluate the effect of a physical intervention on the performance and inter-limb asymmetries of female soccer players.


Eligibility criteria:
inclusion criteria: * caucasian, healthy participant, from 12 to 20 years old, with a history of training at least 3 years. exclusion criteria: * non-caucasian, injury.

Keywords: soccer female lower limb asymmetries strength
phase ii cisplatin + temozolomide in malignant glial tumours in children and adolescents

Conditions: Glioma

Summary: the purpose of this study is to determine whether the combination of temozolomide and cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents


Eligibility criteria:
inclusion criteria: * age from 4th birthday and younger than 21st birthday * histologically documented malignant glial tumour (who classification grade iii and iv) : astrocytoma, oligodendroglioma, oligoastrocytoma and mixed tumours * measurable and evaluable disease by the imaging criteria (mri) * patient not previously treated by either of the two drugs exclusion criteria: * malignant brain stem tumours are excluded
preemptive endoluminal negative pressure in minimally invasive transthoracic esophagectomy

Conditions: Esophageal Cancer; Surgery--Complications; Leak, Anastomotic

Summary: the primary objective of the presponge randomized controlled trial (rct) will be to assess the potential protective effects of preemptive endoscopic negative pressure therapy (enp) on postoperative morbidity in high-risk patients undergoing total minimally invasive transthoracic esophagectomy with gastric pull-up reconstruction and high intrathoracic anastomosis (thoracoscopic and laparoscopic ivor lewis esophagectomy).


Eligibility criteria:
inclusion criteria: we will include adult patients (≥18 years of age) with resectable esophageal cancer (adenocarcinoma or squamous cell carcinoma) with high risk for anastomotic leakage (al) who provided informed consent and are scheduled for minimally invasive transthoracic ivor lewis esophagectomy. robotic-assisted procedures will also be included. patients considered at high risk for al must have at least one of the following risk factors: * american society of anesthesiologists classification (asa) score \>2 * diabetes (insulin dependent or hba1c ≥ 6.5%) * chronic pulmonary disease (first second of forced expiration (fev1)/forced volume vital capacity (fvc) ratio ≤ 70%) * heart failure (left ventricular ejection fraction (lvef) \<55%) * preexisting cardiac arrhythmia (pacemaker or paroxysmal supraventricular tachyarrhythmia) * chronic kidney disease stage 4-5 (glomerular filtration rate (gfr) \< 30ml/min/1.73 m2) * chronic liver disease with treated portal hypertension (porto-caval pressure gradient ≥5-≤10mmhg, including patients with transjugular intrahepatic portosystemic shunt (tips)) * previous radiotherapy or chemo-radiation ≥50gray (gy) (salvage esophagectomy) alternatively, patients must have at least two of the following risk factors: * arteriosclerosis score 2 according to van rossum et al.13 (aorta and coeliac axis) * malnutrition (body mass index (bmi) ≤ 18.5kg/m2) * obesity (bmi ≥ 35kg/m2) * heart failure with preserved ejection fraction (lvef \>55%) * active or former smoking * age \> 65 years * world health organisation (who)/zubrodt score \> 1 * chronic kidney disease stage 2-3 (gfr 30-89 ml/min/1.73 m2) * chronic liver disease without portal hypertension (porto-caval pressure gradient ≤5mmhg) exclusion criteria: * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, or dementia. * patients younger than 18 years * patients undergoing esophagectomy for benign disease or for malignancy other than adenocarcinoma or squamous cell carcinoma * patients scheduled for other technical variants of esophagectomy, such as open, hybrid, or transhiatal procedures (intraoperative conversions to open access surgery will not be excluded) * chronic liver disease with portal hypertension (porto-caval pressure gradient \>10mmhg) * distant organ metastasis (cm+)
pedometers for the enhancement of post cesarean mobility

Conditions: Mobility Limitation

Summary: this is a randomized controlled trial, planned to study the effects of pedometers (digital step counters) on patient mobility following cesarean delivery. the investigators plan to randomize patients at high risk for thromboembolic events to participants with a personalized repeated feedback approach based on pedometer results, versus participants with no feedback to pedometer results.


Eligibility criteria:
inclusion criteria: * patients following cesarean delivery * consent to participation * no medical recommendation for bed rest and limited mobility * meet any of the following criteria for high risk for thromboembolic complications - preeclampsia, chronic disease (reumatic, inflammatory bowel disease), obese, smoker \> 10 cigaretts a day, age \>35, substantial limb varicose, multiple gestation, multiparity (\> deliveries), emergent surgery, thrombophilia. exclusion criteria: * refusal to participate * medical recommendation to limit mobility
tidal neonatal no, vitamins a and d, and infant lung disease - the ad-on study

Conditions: Term Delivery With Preterm Labor, Third Trimester; Term Delivery With Preterm Labor, Unspecified Trimester; Bronchopulmonary Dysplasia

Summary: children born prematurely are of greater risk of developing chronic lung disease (bronchopulmonary dysplasia). with an increase in the amount of premature children, we expect an increasing number of children with bpd. today we do not have many ways of predicting or treating this condition, and the children are usually in hospital for several months after birth. many are dismissed with home oxygen. children with bpd are typically often re-submitted to hospital with respiratory disease the first couple of years, and some of them have problems throughout childhood and into adulthood. other scientists have found a correlation between bpd and chronic obstructive pulmonary disease (copd). the condition as well as the treatment (steroids), are associated with great risk of adverse effects as cerebral palsy, blindness, deafness and mental retardation. the investigators wish to find a safe way to identify the children in greater risk of developing bpd, who could therefore benefit from a more intensive treatment.an early diagnosis would increase the possibility of predicting the prognosis. other studies have proven a connection between both low vitamin a and d and high exhaled nitrogen oxide (no) with lung disease. with this trial the investigators wish to make a reference material for no and vitamins a and d in infants admitted to the neonatal department at two hospitals in denmark, both with and without treatment with nasal continuous positive airway pressure. the investigators furthermore wish to describe an eventual connection between bpd and these factors by examining a large group of children on 7 specific occasions within the first two months of life and at a one year follow up.


Eligibility criteria:
inclusion criteria: cohort inclusion - all term and preterm infants admitted to neonatal (intensive) care unit. gestational age 24-42 weeks. exclusion criteria: 1. children with ciliary dyskinesia, as no is distinguishable lower in these children. 2. children who can not cooperate to the examination. 3. children so dependant on oxygen, that the examination/measurement is not possible. 4. children with pneumothorax 5. children having a diagnosed pneumonia verified by tracheal secrete. 6. children with bigger congenital anomalies

Keywords: neonatal preterm bronchopulmonary dysplasia nasal continuous positive airway pressure (cpap) oxygen vitamin a vitamin d nitrogen oxide (no) reference material
safety, tolerability, pharmacokinetics and pharmacodynamics of tap311 in healthy subjects and dyslipidemic patients

Conditions: Dyslipidemia; Healthy Volunteers

Summary: this study will assess the safety, tolerability, and effect of tap311 on blood lipids in healthy subjects and in patients who have dyslipidemia. the effect of food on tap311 concentration in blood and effect of tap311 administration on simvastatin concentration will also be assessed in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects age 18 to 65 years of age included, and in good health as determined by past medical history, physical examination, electrocardiogram, and laboratory tests at screening. * or untreated dyslipidemic patients. * subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (bmi) within the range of 18 - 36 kg/m2. * able to communicate well with the investigator, to understand and comply with the requirements of the study. exclusion criteria: * use of other investigational drugs at the time of enrollment. * active treatment for type 1 diabetes or type 2 diabetes mellitus. * a past medical history of ecg abnormalities, documented cardiac arrhythmias or cardiovascular diseases. * history of malignancy of any organ system, treated or untreated, within the past 5 years. * pregnant or nursing (lactating) women. * smokers. * use of any prescription drugs, herbal supplements and/or over-the-counter (otc) medication, dietary supplements. * history of drug or alcohol abuse within the 12 months prior to dosing. * any surgical or medical condition, acute or unstable chronic disease which may, based on the investigator's opinion, jeopardize the patient in case of participation in the study other protocol-defined inclusion/exclusion criteria may apply.

Keywords: high cholesterol levels hyperlipidemia high-density lipoprotein low-density lipoprotein simvastatin
a drug drug interaciton study of imrecoxib and warfarin in healthy volunteers

Conditions: Knee Osteoarthritis

Summary: the objective of this study was to determine the effects of imrecoxib, an anti-infiammatory/analgesic agent that primarily inhibits cox-2 and not cox-1 at therapeutic doses, on the steady-state pharmacokinetic profile and hypoprothrombinemic effect of warfarin in healthy volunteers.

this is a single center open label study to assess the effect of imrecoxib on the pk of warfarin in healthy volunteers. the goals of this study are as follows: assess the pk of warfarin when administered alone ,and with imrecoxib ; assess inr of warfarin when administered alone, and with imrecoxib; to assess the effect of imrecoxib on the pk/pd of warfarin, to assess the safety and tolerability of warfarin administered with imrecoxib.

Eligibility criteria:
inclusion criteria: adult males aged 18 to 40 years,with bmi 19\~24. subjects who, in the opinion of the investigator, are healthy as determined by medical history, physical examination, and 12 lead ecg. willing and able to provide written informed consent. exclusion criteria: history of hypersensitivity to imrecoxib and its components. history or current clinically important systemic illnesses, including but not limited to cardiovascular, pulmonary, hepatobiliary, renal, hematological, gastrointestinal, endocrinological, immunological, dermatological, neurological, or psychiatric diseases, or any conditions that may place the subject at increased risk as determined by the investigator. any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs. history of alcohol dependent, habitual heavy users of caffeinated beverages judged by the investigator. have had significant blood loss (\>200ml) or have donated 1 or more units of blood or plasma within 12 weeks prior to study entry. have a positive test at screening for human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or hepatitis c virus antibody (hcvab). have used any drugs or substances (including herbal supplements) known to inhibit or induce cytochrome (cyp) p450enzymesincluding cyp3a4, cyp2c8 and cyp2c9 within 4 weeks prior to the first dose and throughout the study.